Medically Reviewed by Expert Board

This page was fact checked by our expert Medical Review Board for accuracy and objectivity. Read more about our editorial policy and review process.

This article was last modified on
Learn more about...

What is ovarian cancer?

Ovarian cancer is the uncontrolled growth of cells within a woman’s ovary. The ovaries are reproductive glands that are located on either side of the uterus in the lower abdomen.

The ovaries have two main functions:

  • To produce the hormones estrogen and progesterone that are responsible for the development of secondary sexual features (e.g., breast growth, pubic hair) and regulation of the reproductive cycle
  • To develop and release an egg into the fallopian tube once a month during childbearing years

Ovarian cancer is the fifth most common cause of cancer death in women. According to the American Cancer Society (ACS), the life-time risk of developing ovarian cancer is about 1 in 78. ACS estimates that about 22,500 new cases are diagnosed each year in the United States and nearly 14,000 women die of it. Invasive ovarian cancer is a more common cause of death than the more prevalent and easily detected cervical cancer and uterine cancer. Ovarian cancer is more difficult to detect, so it is often diagnosed at later stages, when it is more difficult to treat.

Ovarian tumors can be non-cancerous (benign) or cancerous (malignant). It is not usually possible to tell whether a tumor is cancerous until the ovary has been biopsied or removed or the cancer has spread to other parts of the body. Ovarian tumors fall into three categories:

  • Epithelial tumors (majority of ovarian tumors) – begin in the epithelial cells covering the outside of the ovaries
  • Germ cell tumors (less than 2% of all ovarian tumors) – occur in the egg-producing cells and are more often seen in younger women
  • Stromal tumors (about 1% of all ovarian tumors) – derive from connective tissues of the ovary that produce estrogen and progesterone

While benign tumors do not spread (metastasize), cancerous (malignant) ovarian tumors will spread if left undiagnosed and untreated – first throughout the ovary, then to the uterus, bladder, rectum, and the lining of the abdomen. Eventually, cancerous cells will reach the lymph nodes and spread throughout the body.

About Ovarian Cancer

Risk Factors

The main risk factor for ovarian cancer is a family history of ovarian cancer on either your mother’s or father’s side of the family. According to the American Cancer Society, about 5% to 10% of ovarian cancers develop from an inherited (genetic) risk. Some examples include:

  • Hereditary breast and ovarian cancer syndrome—inherited harmful (pathogenic) genetic variants in the BRCA1 and BRCA2 genes are associated with a significantly increased lifetime risk of developing ovarian cancer. For women with BRCA1 pathogenic variants, the risk is estimated to be 35-70% and for women with BRCA2 pathogenic variants it is 10-30%. Women without these pathogenic variants have a lifetime risk of about 2%.
  • Hereditary nonpolyposis colon cancer (Lynch syndrome)—inherited pathogenic variants in several genes (MLH1, MLH3, MSH2, MSH6, TGFBR2, PMS1, PMS2) are associated mainly with an increased risk of colon cancer, but women may also have a higher risk of ovarian cancer (a lifetime risk of about 10%).

Other risk factors include:

  • Age—about half the ovarian cancers are found in women 63 years of age or older. Most ovarian cancers develop after menopause.
  • Race—ovarian cancers are more common in Caucasian women than in African American women.
  • Personal history of breast cancer
  • Not having children or having children after age 35
  • Being overweight or obese
  • Taking hormone replacement therapy
  • Having fertility treatment

Factors that may be associated with decreased risk include taking oral contraceptives, having children when younger than age 26, and breastfeeding.

Signs and Symptoms

The primary reasons ovarian cancers go undetected are that there is no reliable screening test and the symptoms are often not noticeable and fairly non-specific, meaning there are many non-cancerous conditions that can cause similar symptoms and often be difficult to tell apart. Some examples of signs and symptoms include:

  • Abdominal discomfort, pressure, bloating, or swelling
  • Strong, frequent urge to urinate and/or change in bowel habits
  • Pelvic pain or discomfort
  • Loss of appetite, indigestion, gas or nausea

It is important to have regular checkups and to consult with a healthcare practitioner if signs and symptoms develop.


Laboratory Tests

Currently, there is no specific screening test for ovarian cancer. The U.S. Preventive Services Task Force (USPSTF) recommends against screening women for ovarian cancer. This recommendation applies to asymptomatic women (the general population) but not to women at a high risk of developing ovarian cancer, such as those with a known harmful (pathogenic) genetic variant (e.g., BRCA1/2 variant). Women with increased risk may be monitored with a combination of transvaginal ultrasounds and blood tests for the tumor marker CA-125.

The need for a reliable method for early detection of ovarian cancer among asymptomatic women continues to drive ongoing research. Molecular (gene) tests and multimarker approaches are being explored to improve early detection of ovarian cancers. In the meantime, regular physicals, pelvic exams, and an awareness of family history and symptoms are important.

Tests for increased risk

Women with a strong family history or ethnicity associated with ovarian cancer may receive genetic counseling and have genetic testing done. A common example is BRCA1 and BRCA2 testing. These tests detect harmful genetic variants that are known to increase the risk of breast and ovarian cancer. Only about 0.2% of the U.S. population carries a harmful BRCA1 or BRCA2 variant. Because of this, genetic testing is not recommended for the general population.


If an abnormality is found, such as a growth detected during an ultrasound, and ovarian cancer is suspected, a biopsy is typically required to confirm the diagnosis. A sample of the growth is removed during surgery and sent to the laboratory. A pathologist uses a microscope to examine the sample and determine whether cancer is present.


  • CA-125 (Cancer antigen 125) – this is a tumor marker primarily used to monitor therapy during treatment for ovarian cancer. CA-125 is also used to detect whether cancer has come back after treatment is complete. A series of CA-125 tests that shows rising or falling levels is often more useful than a single result.
  • HE4 (Human epididymis protein 4) – a relatively new tumor marker that shows promise. It may be used along with CA-125 to monitor women who have been treated for epithelial ovarian cancer. In order for HE4 to be useful as a tumor marker, it must be elevated prior to treatment.

Other tests may be ordered to help monitor different types of ovarian tumors. The tests may help determine whether treatment (e.g., surgery, chemotherapy) is successful and whether cancer has returned. Some examples include:

Non-laboratory Tests

Imaging tests that may be used to evaluate the ovaries include:

  • Ultrasound (pelvic and/or transvaginal) – uses sound waves to create a picture of the uterus and ovaries; it can help determine whether an ovarian growth is likely to be a cancer or a fluid-filled cyst.
  • CT scan (computerized tomography) or X-rays may be used to see if the cancer has spread.
  • MRI (magnetic resonance imaging) may be used to see if the cancer has spread.

Staging and Treatment

If cancer is found, surgery to remove the cancerous tissue is performed (oophorectomy). Additional tissues may be removed to determine the stage of the disease, most commonly the fallopian tubes (salpingectomy). Ovarian cancer staging is complex but generally, one of four stages of cancer is identified, depending on the spread of the tumor. They are:

  • Stage 1 – this stage includes cancer present in one or both ovaries or fallopian tubes as well as cancer that has spread to the outside surface of these organs and/or in pelvic or abdominal fluid. However, the cancer has not spread to nearby organs or lymph nodes or distant sites (about 20% of ovarian cancers diagnosed with best prognostic outcomes).
  • Stage 2 – this stage includes cancer that has spread to nearby pelvic organs such as the uterus, bladder, rectum and/or lower colon but not to nearby lymph nodes or distant organs.
  • Stage 3 – this stage includes cancer that has spread to the abdomen lining or surrounding lymph nodes.
  • Stage 4 – cancer has spread to other organs beyond the abdomen.

Treatment usually depends on the type and stage of the cancer. The main treatment is surgery and may also include chemotherapy, hormone therapy, targeted therapy, and/or sometimes radiation treatments.

Ovarian cancer treatment is constantly evolving. New drugs, immunotherapies, and bone marrow transplants are being studied for their effectiveness. A woman’s healthcare provider and/or cancer team can help determine the treatment course that is right for her. For more information about treatment, see the links in Related Content.

View Sources

Sources Used in Current Review

Current review performed by Mutasim Elfahal, PhD, DABCC, Lahey Hospital & Medical Center, Burlington, MA and the LTO Editorial Review Board.

(April 2018) Ovarian Cancer. American Cancer Society. Available online at Accessed December 2019.

Powell SN, Kachnic LA. Roles of BRCA1 and BRCA2 in homologous recombination, DNA replication fidelity and the cellular response to ionizing radiation. Oncogene. 2003 Sep 1;22(37):5784-91. Review. PubMed PMID: 12947386.

Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian C, Bradley W, Mathews C, Liu J, Lowe ES, Bloomfield R, DiSilvestro P. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. NEJM 2018 Dec 27;379(26):2495-2505. Oct 21. PubMed PMID: 30345884.

Christina Bennett, MS. Pembrolizumab Combo Shows Clinical Benefit for Recurrent Epithelial Ovarian Cancer. March 19, 2019, SGO, Gynecologic Cancers, News, Ovarian Cancer, Cancer Network. Accessed December 2019.

(October 2019) ARUP Consult. Ovarian Cancer. Available online at Accessed December 2019.

Sources Used in Previous Reviews

Thomas, Clayton L., Editor (1997). Taber’s Cyclopedic Medical Dictionary. F.A. Davis Company, Philadelphia, PA [18th Edition].

Pagana, Kathleen D. & Pagana, Timothy J. (2001). Mosby’s Diagnostic and Laboratory Test Reference 5th Edition: Mosby, Inc., Saint Louis, MO.

(2000 October 20). Ovarian Cancer. American Cancer Society. Ovarian Cancer Detailed Guide [On-line information]. PDF available for download at

(2000 April 19). Ovarian Cancer. MedlinePlus Health Information [On-line information]. Available online at

(2002 January 22, Updated). What You Need to Know About Ovarian Cancer. National Cancer Institute [On-line information]. Available online at

(2001 April 20.) What is Ovarian Cancer? [On-line information]. Available online at

Department of Health and Human Services. Common Uterine Conditions, Options for Treatment. Agency for Healthcare Research and Quality [On-line information]. Available online at

Cancer Screening Guidelines. American Family Physician (AAFP) [On-line journal]. Available online at

(Revised 2008 January 19). What is Ovarian Cancer? American Cancer Society [On-line information]. Available online at Accessed April 2009.

(2006 July 17). What You Need to Know About Ovarian Cancer. National Cancer Institute [On-line information]. Available online at Accessed April 2009.

(Revised 2009 March). Ovarian Cancer. Centers for Disease Control and Prevention [On-line information]. PDF available for download at Accessed April 2009.

Mayo Clinic Staff (2008 November 11). Ovarian Cancer. [On-line information]. Available online at Accessed April 2009.

Nelson, R. (2009 April 6). Ovarian Cancer Screening Fails to Detect Early-Stage Disease. Medscape Medical News. Available online at Accessed April 2009.

Gershenson, D. and Ramirez, P. (Revised 2008 November). Ovarian Cancer. The Merck Manual for Healthcare Professionals available online at Accessed April 2009.

(Revised 2012 October 5). Ovarian Cancer, Detailed Guide. American Cancer Society [On-line information]. Available online at Accessed October 2012.

(Modified 2011 September 30). Ovarian Cancer Screening (PDQ®) Patient Version. National Cancer Institute [On-line information]. Available online at Accessed October 2012.

(Modified 2012 January 26). Ovarian Cancer Screening (PDQ®) National Cancer Institute [On-line information]. Available online at Accessed October 2012.

Green, A. (Updated 2012 September 26). Ovarian Cancer. Medscape Reference [On-line information]. Available online at Accessed October 2012.

Grenache, D. et. al. (Updated 2012 May). Ovarian Cancer. ARUP Consult [On-line information]. Available online at Accessed October 2012.

(Updated 2012 August 1). Fazal Hussain, F. and Homoud, H. Gynecologic Tumor Markers Tumor Marker Overview. Medscape Reference [On-line information]. Available online at Accessed October 2012.

Danforth, K. et. al. (2012 April). Addendum to Screening for Ovarian Cancer: Evidence Update for the U.S. Preventive Services Task Force Reaffirmation Recommendation Statement. USPSTF [On-line information]. Available online at Accessed October 2012.

2016 review performed by Pradip Datta, PhD, DABCC.

(February 4, 2016) American Cancer Society. Ovarian Cancer. Available online at Accessed on 2/9/16.

(2015) American Society of Clinical Oncology (ASCO). Available online at Accessed on 2/9/16.

Suh KS, Park SW, Castro A, et al. Ovarian cancer biomarkers for molecular biosensors and translational medicine. Expert Rev Mol Diagn. 2010;10(8):1069-1083. Available online at Accessed on 2/9/16.

(2015) Mayo Clinic. Available online at Accessed on 2/9/16.